Eli Lilly’s (NYSE:LLY) newly approved Alzheimer’s drug Kisunla could generate peak sales of up to $7.1B for the company and will help diversify the drugmaker's revenue stream, according to BMO.

Eli Lilly unexpectedly lowered its full-year 2024 guidance. The miss appears to stem from a lack of the typical December ...

Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...

DBS analyst Nico Chen has maintained their bullish stance on LLY stock, giving a Buy rating on January 21.Invest with Confidence: Follow ...

As evidence has mounted that new diabetes and weight loss drugs can provide a variety of health benefits, the FDA has ...

Eli Lilly shares dropped after the drugmaker cut its 2024 revenue guidance, citing lower-than-expected demand for its obesity ...

Eli Lilly cut its 2024 revenue guidance, saying demand for its obesity and diabetes drugs had not met its lofty expectations. Eli Lilly expects about $3.5 billion in revenue for its diabetes ...

Eli Lilly now expects revenue to be approximately ... as it has several new drugs to treat conditions like cancer, ulcerative colitis, and Alzheimer's disease. If Lilly is correct in its ...